用去纤苷需要注意什么事项呢？

Defibrotide (defiteli) is a single-stranded oligonucleotide mixture with anti-thrombotic and fibrinolytic effects. It is a DNA-derived anticoagulant used for the treatment of hepatic veno-occlusive disease and hematopoietic stem cell transplantation in renal or pulmonary insufficiency. It was approved for marketing in the United States in 2016. Defibrinoside is a new drug for the treatment of hepatic veno-occlusive disease (HVOD). It has the effects of anticoagulation, promoting fibrinolysis, and promoting vascularization.

Defibrotide (defiteli) is currently recognized as the most promising new drug for the treatment of hepatic veno-occlusive disease (HVOD) after hematopoietic stem cell transplantation (HSCT). By reducing the expression of cell adhesion molecules on the surface of endothelial cells, it can reduce the adhesion of leukocytes to vascular endothelial cells and reduce the inflammatory damage of endothelial cells.

Defibrotide is a prescription drug, and precautions during treatment should also be paid attention to.

1. Bleeding:

Defibrotide (defiteli) increases plasmin activity in vitro and may increase the risk of bleeding after hematopoietic stem cell transplantation (HSCT) in patients with VOD. Do not initiate defibrotide in patients with active bleeding. Monitor patients for signs of bleeding. If the patient bleeds, discontinue defibrotide, treat the cause, and provide supportive care until bleeding has stopped.

Concomitant use of defibrotide and a systemic anticoagulant or fibrinolytic therapy (excluding use for routine maintenance or central venous line reopening) may increase the risk of bleeding. Discontinue anticoagulants and fibrinolytics before defibrotide therapy, and consider delaying initiation of defibrotide administration until the effects of the anticoagulant have lessened.

2. Hypersensitivity reaction:

Hypersensitivity reactions have occurred in less than 2% of patients treated with defibrotide (defiteli). These reactions include rash, urticaria, and angioedema. One case of anaphylactic reaction was reported in a patient who had previously received defibrotide. Monitor patients for hypersensitivity reactions. Especially if there is a history of previous exposure. If a serious hypersensitivity reaction occurs, discontinue use and follow standard medical care and monitor until symptoms resolve.